Acute Lymphoid Leukemia: Clinical Trials

11 trials for Acute Lymphoid Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting, 3 completed, 1 active not recruiting, 1 unknown. 11 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Recruiting 5, Completed 3, Active not recruiting 1, Unknown 1, Withdrawn 1
Phase 22Recruiting 2

Follow Acute Lymphoid Leukemia: new trials by email Literature Review of Acute Lymphoid Leukemia trials Research Report on Acute Lymphoid Leukemia

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Prophylactic DLI-X for Leukemia Relapse After HCT
Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Phase 1RecruitingUniversity of Arizona1802026-10-262026-10-29
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
ORCA-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1RecruitingStanford University242025-12-012026-06-23
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
CD19 Directed CAR T Cell - Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia
Phase 1RecruitingUniversity of Colorado, Denver292024-01-242026-03-11
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1302022-12-282026-10-26
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1 / Phase 2RecruitingUniversity of Florida402022-08-162026-10-30
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3 - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1WithdrawnMedigene AG2020-07-022021-10-08
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1Active not recruitingOrca Biosystems, Inc.1552019-11-212026-08-14
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Zilovertamab vedotin - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Phase 1CompletedVelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)912019-03-142024-01-12
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell
Phase 1CompletedNational Cancer Institute (NCI)542018-03-262025-06-04
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
Cytarabine, Deferasirox - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1UnknownIsfahan University of Medical Sciences402016-05-012016-02-25
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
OPB-51602 - Multiple Myeloma, Non-Hodgkin Lymphoma
Phase 1CompletedOtsuka Pharmaceutical Co., Ltd.202011-04-012015-06-08

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (11)  ·  Leukemia, Myeloid, Acute (8)  ·  Lymphoma, Non-Hodgkin (5)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4)  ·  Lymphoma (4)  ·  Myelodysplastic Syndromes (4)  ·  Burkitt Lymphoma (3)  ·  Hematologic Neoplasms (3)  ·  Leukemia, B-Cell (3)  ·  Leukemia, Biphenotypic, Acute (3)  ·  Lymphoma, B-Cell (2)  ·  Multiple Myeloma (2)  ·  Philadelphia Chromosome (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Disease (1)

Broader conditions

Hematologic Diseases (11)  ·  Hemic and Lymphatic Diseases (11)  ·  Immune System Diseases (11)  ·  Immunoproliferative Disorders (11)  ·  Lymphatic Diseases (11)  ·  Lymphoproliferative Disorders (11)  ·  Neoplasms (11)  ·  Neoplasms by Histologic Type (11)  ·  Leukemia (10)  ·  Leukemia, Lymphoid (10)  ·  Leukemia, Myeloid (8)  ·  Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Bone Marrow Diseases (6)  ·  Chronic Disease (6)

Interventions

Cyclophosphamide (2)  ·  fludarabine (2)  ·  Acetaminophen (1)  ·  Antiemetics (1)  ·  Blood Component Removal (1)  ·  Cytarabine (1)  ·  Deferasirox (1)  ·  Diphenhydramine (1)  ·  Echocardiography (1)  ·  Electrocardiography (1)  ·  Magnetic Resonance Imaging (1)  ·  fludarabine phosphate (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Isfahan University of Medical Sciences (1)  ·  Medigene AG (1)  ·  Orca Biosystems, Inc. (1)  ·  Otsuka Pharmaceutical Co., Ltd. (1)  ·  Stanford University (1)  ·  University of Arizona (1)  ·  University of Colorado, Denver (1)  ·  University of Florida (1)  ·  VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)

Countries

United States (8)  ·  Japan (1)  ·  Netherlands (1)

Top investigators

Alireza Eishi, Med student (1)  ·  Emmanuel Katsanis, MD (1)  ·  Jordan Milner, MD (1)  ·  Lori Muffly (1)  ·  Mahnaz Danesh, MD (1)  ·  Mathew Angelos, MD (1)  ·  Nirali N Shah, M.D. (1)  ·  Peter van Balen, MD (1)  ·  Rene Goedkoop, MD (1)  ·  Sara K Silbert, M.D. (1)  ·  Shaghayegh Haghjoo Javanmard, MD, PHD (1)  ·  Valiollah Mehrzad, MD (1)

Results publications

PMID 34398557, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 38319241, PMID 38376944, PMID 42248607